Lucy D. Mastrandrea, MD, PhD, professor of pediatrics in the Jacobs School of Medicine and Biomedical Sciences, has been ...

A new University of California San Diego study offers compelling evidence that glucagon-like peptide-1 (GLP-1) receptor ...

There’s a reason why millions of people in the UK are on weight-loss injections – and it’s not because we’re all weak, writes ...

Shares of Amgen are up nearly 26% this year and have soared 11% just over the past week.

Did people really mean it when they said being fat is fine, and they don't want to be thin? GLP-1 drugs may be changing this ...

WASHINGTON -- Treatment with the investigational GLP-1/glucagon dual receptor agonist pemvidutide led to resolution of ...

GLP-1 receptor agonists — the drug class that includes Ozempic, Wegovy and Mounjaro — were linked to improved survival among colon cancer patients in a new observational study from UC San Diego.

Oregon and federal leaders must take a dual approach: Expanding safe, affordable access to FDA-approved anti-obesity medications prescribed by health professionals, while Continuing to shut down ...

A new University of California San Diego study offers compelling evidence that glucagon-like peptide-1 (GLP-1) receptor ...

Study also revealed no increased risk for major adverse cardiovascular events for patients on a GLP-1 RA vs those not on a GLP-1 RA.

Opinion: What is Kennedy’s problem with medication?

Companies don’t generally cut prices out of generosity.